BioSpace News Archive

- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced positive results of the first 230 patients enrolled in its FLASH study. Interim data of this real world pulmonary embolism (“PE”) population, including high- and intermediate-risk patients, was obtained across 19 US sites. Results were

Hemogenyx Pharmaceuticals plc (“Hemogenyx Pharmaceuticals” or the “Company”) Presentation at the American Society of Hematology Meeting

Midatech Pharma PLC, an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce encouraging headline results from a Phase I study at the University of California, San Francisco in patients with Diffuse Intrinsic Pontine Glioma .

Oncopeptides AB announces that the Company has submitted an Investigational New Drug application to the U.S. Food and Drug Administration, for OPD5 - a second drug candidate based on the proprietary Peptide Drug Conjugate platform.

Raises US$8M from US-based investor Acorn Bioventures and current shareholders, bringing total raised in last six months to US$14.6M

Itamar Medical Ltd., a leading medical device and digital health company focused on the diagnosis of sleep apnea and other respiratory sleep disorders, announced that Shane Brown has been appointed President – U.S., effective immediately.

Mevion Medical Systems is pleased to announce it has entered a partnership agreement with Hermes Advanced Therapy Systems Corp. for the distribution of the MEVION S250i Proton Therapy System® in Taiwan and Southeast Asia, including Malaysia, Thailand, and Singapore.

– New in vitro data demonstrating antiviral activity with lead compound CC-42344 against Xofluza (baloxavir)-resistant H1N1 strain – – Company continues to advance IND-enabling studies for Phase 1 clinical study in 2021 –

Highlights : Study will assess safety and efficacy of RECCE ® 327 against a broad range of infectious bacteria on chronic burn wounds in up to 30 patients over two week period Study anticipated to be sponsored by South Metropolitan Health Service , Department of Health, Government of Western Australia (WA) Fiona Stanley Hospital ( B urns U nit) in Perth Western Australia identified as study site SYDNEY, Australia, Oct. 19, 2020 (GLOBE NEWSWIRE)

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, announced the appointment of Professor Jean-Charles Soria, M.D., Ph.D., to its Board of Directors.